Roth MKM Maintains Buy on Mind Medicine, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes maintains a Buy rating on Mind Medicine (NASDAQ:MNMD) and keeps the price target at $36.
July 24, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jason Wittes maintains a Buy rating on Mind Medicine (NASDAQ:MNMD) and keeps the price target at $36.
The reaffirmation of a Buy rating and a $36 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100